Vascular disrupting effects of combretastatin A4 phosphate on murine endometriotic lesions

Fertility and Sterility

Volumn 100, Issue 5, 2013, Pages

  Feng, Dilu ^a   Menger, Michael D ^a   Laschke, Matthias W ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

angiogenesis; combretastatin A4 phosphate (CA4P); Endometriosis; vascular disrupting agents; vascularization

Indexed keywords

COMBRETASTATIN A4 PHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY DENSITY; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; ENDOMETRIOSIS; FEMALE; FLUORESCENCE MICROSCOPY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; ISOGRAFT; MICROVASCULARIZATION; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE;

EID: 84887103646     PISSN: 00150282     EISSN: 15565653     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2013.07.1967     Document Type: Article

References (34)

1. L.C. Giudice, and L.C. Kao Endometriosis Lancet 364 2004 1789 1799
2. P.G. Groothuis, A.W. Nap, E. Winterhager, and R. Grümmer Vascular development in endometriosis Angiogenesis 8 2005 147 156
3. M.W. Laschke, and M.D. Menger Anti-angiogenic treatment strategies for the therapy of endometriosis Hum Reprod Update 18 2012 682 702
4. M. Nisolle, F. Casanas-Roux, V. Anaf, J.M. Mine, and J. Donnez Morphometric study of the stromal vascularization in peritoneal endometriosis Fertil Steril 59 1993 681 684
5. A. Van Langendonckt, J. Donnez, S. Defrère, G.A. Dunselman, and P.G. Groothuis Antiangiogenic and vascular-disrupting agents in endometriosis: pitfalls and promises Mol Hum Reprod 14 2008 259 268
6. M.A. Spear, P. LoRusso, A. Mita, and M. Mita Vascular disrupting agents (VDA) in oncology: advancing towards new therapeutic paradigms in the clinic Curr Drug Targets 12 2011 2009 2015
7. P. Hinnen, and F.A. Eskens Vascular disrupting agents in clinical development Br J Cancer 96 2007 1159 1165
8. G. Nagaiah, and S.C. Remick Combretastatin A4 phosphate: a novel vascular disrupting agent Future Oncol 6 2010 1219 1228
9. C.M. West, and P. Price Combretastatin A4 phosphate Anticancer Drugs 15 2004 179 187
10. D.W. Siemann, D.J. Chaplin, and P.A. Walicke A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P) Expert Opin Investig Drugs 18 2009 189 197
11. J.A. Sosa, J. Balkissoon, S.P. Lu, P. Langecker, R. Elisei, and B. Jarzab Thyroidectomy followed by fosbretabulin (CA4P) combination regimen appears to suggest improvement in patient survival in anaplastic thyroid cancer Surgery 152 2012 1078 1087
12. J.I. Lim Macular degeneration: the latest in current medical management Retina 26 2006 S17 S20
13. M.W. Laschke, and M.D. Menger In vitro and in vivo approaches to study angiogenesis in the pathophysiology and therapy of endometriosis Hum Reprod Update 13 2007 331 342
14. M.W. Laschke, A.E. Vorsterman van Oijen, C. Scheuer, and M.D. Menger In vitro and in vivo evaluation of the anti-angiogenic actions of 4-hydroxybenzyl alcohol Br J Pharmacol 163 2011 835 844
15. M.W. Laschke, B. Vollmar, and M.D. Menger The dorsal skinfold chamber: window into the dynamic interaction of biomaterials with their surrounding host tissue Eur Cell Mater 22 2011 147 164
16. D. Feng, S. Welker, C. Körbel, J. Rudzitis-Auth, M.D. Menger, and M. Montenarh Protein kinase CK2 is a regulator of angiogenesis in endometriotic lesions Angiogenesis 15 2012 243 252
17. M. Baker, and H. Wayland On-line volume flow rate and velocity profile measurement for blood in microvessels Microvasc Res 7 1974 131 143
18. A. Hasani, and N. Leighl Classification and toxicities of vascular disrupting agents Clin Lung Cancer 12 2011 18 25
19. I.M. Subbiah, D.J. Lenihan, and A.M. Tsimberidou Cardiovascular toxicity profiles of vascular-disrupting agents Oncologist 16 2011 1120 1130
20. A. Hollebecque, C. Massard, and J.C. Soria Vascular disrupting agents: a delicate balance between efficacy and side effects Curr Opin Oncol 24 2012 305 315
21. M.W. Laschke, A. Elitzsch, B. Vollmar, and M.D. Menger In vivo analysis of angiogenesis in endometriosis-like lesions by intravital fluorescence microscopy Fertil Steril 84 Suppl 2 2005 1199 1209
22. H. Katayama, T. Katayama, K. Uematsu, M. Hiratsuka, M. Kiyomura, and Y. Shimizu Effect of dienogest administration on angiogenesis and hemodynamics in a rat endometrial autograft model Hum Reprod 25 2010 2851 2858
23. G.M. Tozer, C. Kanthou, C.S. Parkins, and S.A. Hill The biology of the combretastatins as tumour vascular targeting agents Int J Exp Pathol 83 2002 21 38
24. D.J. Chaplin, and G.J. Dougherty Tumour vasculature as a target for cancer therapy Br J Cancer 80 Suppl 1 1999 57 64
25. S. Matsuzaki, M. Canis, T. Murakami, P. Dechelotte, M.A. Bruhat, and K. Okamura Immunohistochemical analysis of the role of angiogenic status in the vasculature of peritoneal endometriosis Fertil Steril 76 2001 712 716
26. A.W. Nap, A.W. Griffioen, G.A. Dunselman, J.C. Bouma-Ter Steege, V.L. Thijssen, and J.L. Evers Antiangiogenesis therapy for endometriosis J Clin Endocrinol Metab 89 2004 1089 1095
27. C.M. Becker, N. Rohwer, T. Funakoshi, T. Cramer, W. Bernhardt, and A. Birsner 2-methoxyestradiol inhibits hypoxia-inducible factor-1{alpha} and suppresses growth of lesions in a mouse model of endometriosis Am J Pathol 172 2008 534 544
28. A. Capobianco, A. Monno, L. Cottone, M.A. Venneri, D. Biziato, and F. Di Puppo Proangiogenic Tie2(+) macrophages infiltrate human and murine endometriotic lesions and dictate their growth in a mouse model of the disease Am J Pathol 179 2011 2651 2659
29. M.W. Laschke, C. Giebels, R.M. Nickels, C. Scheuer, and M.D. Menger Endothelial progenitor cells contribute to the vascularization of endometriotic lesions Am J Pathol 178 2011 442 450
30. C.C. Wang, H. Xu, G.C. Man, T. Zhang, K.O. Chu, and C.Y. Chu Prodrug of green tea epigallocatechin-3-gallate (Pro-EGCG) as a potent anti-angiogenesis agent for endometriosis in mice Angiogenesis 16 2013 59 69
31. C.C. Reyes-Aldasoro, I. Wilson, V.E. Prise, P.R. Barber, M. Ameer-Beg, and B. Vojnovic Estimation of apparent tumor vascular permeability from multiphoton fluorescence microscopic images of P22 rat sarcomas in vivo Microcirculation 15 2008 65 79
32. Y. Boucher, L.T. Baxter, and R.K. Jain Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy Cancer Res 50 1990 4478 4484
33. X. He, S. Li, H. Huang, Z. Li, L. Chen, and S. Ye A pharmacokinetic and safety study of single dose intravenous combretastatin A4 phosphate in Chinese patients with refractory solid tumours Br J Clin Pharmacol 71 2011 860 870
34. G.M. Tozer, V.E. Prise, J. Wilson, M. Cemazar, S. Shan, and M.W. Dewhirst Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability Cancer Res 61 2001 6413 6422